MDWD vs TRLV
MediWound Ltd. and Trulieve Cannabis Corp., side by side — 7 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | MDWD | TRLV |
|---|---|---|
| Revenue | $17.0M | $1.2B |
| Net income | $-23.9M | $-122.2M |
| Gross margin | 19.2% | 60.2% |
| Net margin | −140.8% | −10.3% |
| Return on equity | −63.9% | −10.2% |
| Diluted EPS | −$2.10 | −$0.58 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $-21.6M | $228.6M |
| Equity | · | · |
| Net debt / equity | · | −0.10× |
| Current ratio | 2.33× | 4.43× |
| Revenue CAGR 5y | −4.9% | 17.8% |
| Profit CAGR 5y | · | · |
TRLV bills 69.6× the revenue of MDWD, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
7 years side by side
| Fiscal year | MDWD | TRLV |
|---|---|---|
| FY2025 | $17.0M | $1.2B |
| FY2024 | $20.2M | $1.2B |
| FY2023 | $18.7M | $1.1B |
| FY2022 | $26.5M | $1.2B |
| FY2021 | $23.8M | $931.9M |
| FY2020 | $21.8M | $521.5M |
| FY2019 | $31.8M | $252.8M |
Bottom line
| Fiscal year | MDWD | TRLV |
|---|---|---|
| FY2025 | $-23.9M | $-122.2M |
| FY2024 | $-30.2M | $-160.6M |
| FY2023 | $-6.7M | $-533.1M |
| FY2022 | $-19.6M | $-252.7M |
| FY2021 | $-13.6M | $17.4M |
| FY2020 | $-9.2M | $63.0M |
| FY2019 | $5.0M | $53.1M |
7 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$1,164,221,000 | TRLV |
| FY2024 | −$1,166,268,000 | TRLV |
| FY2023 | −$1,110,507,000 | TRLV |
| FY2022 | −$1,191,733,000 | TRLV |
| FY2021 | −$908,171,000 | TRLV |
| FY2020 | −$499,770,000 | TRLV |
| FY2019 | −$221,030,000 | TRLV |
TRLV has reported the higher revenue in every one of these 7 fiscal years. The gap has widened since the earliest year compared.
7 of 11 comparable fiscal years — a year missing data on either side is not counted.
7 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −130.5 pp | TRLV |
| FY2024 | −135.9 pp | TRLV |
| FY2023 | +11.3 pp | MDWD |
| FY2022 | −53.2 pp | TRLV |
| FY2021 | −58.9 pp | TRLV |
| FY2020 | −54.3 pp | TRLV |
| FY2019 | −5.4 pp | TRLV |
The higher net margin has changed hands between MDWD and TRLV over this period.
7 of 10 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MDWD's net margin has been more volatile than TRLV's over the 7 comparable fiscal years — 54.5 percentage points of standard deviation against 21.0.
7 of 10 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between MDWD and TRLV over these 7 fiscal years — MDWD led in 1 and TRLV in 6.
7 of 10 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MDWD's return on equity has been more volatile than TRLV's over the 5 comparable fiscal years — 48.8 percentage points of standard deviation against 25.8.
5 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between MDWD and TRLV over these 5 fiscal years — MDWD led in 2 and TRLV in 3.
5 of 11 comparable fiscal years — a year missing data on either side is not counted.